Form 8-K - Current report:
SEC Accession No. 0001193125-19-322605
Filing Date
2019-12-23
Accepted
2019-12-23 16:06:39
Documents
12
Period of Report
2019-12-20
Items
Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers

Document Format Files

Seq Description Document Type Size
1 8-K d839477d8k.htm   iXBRL 8-K 28509
  Complete submission text file 0001193125-19-322605.txt   150934

Data Files

Seq Description Document Type Size
2 XBRL TAXONOMY EXTENSION SCHEMA lgnd-20191220.xsd EX-101.SCH 3065
3 XBRL TAXONOMY EXTENSION LABEL LINKBASE lgnd-20191220_lab.xml EX-101.LAB 18140
4 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE lgnd-20191220_pre.xml EX-101.PRE 11405
8 EXTRACTED XBRL INSTANCE DOCUMENT d839477d8k_htm.xml XML 3422
Mailing Address 3911 SORRENTO VALLEY BLVD SUITE 110 SAN DIEGO CA 92121
Business Address 3911 SORRENTO VALLEY BLVD SUITE 110 SAN DIEGO CA 92121 858-550-7500
LIGAND PHARMACEUTICALS INC (Filer) CIK: 0000886163 (see all company filings)

EIN.: 770160744 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-33093 | Film No.: 191306043
SIC: 2834 Pharmaceutical Preparations